These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28286052)

  • 1. A systems biology approach to overcome TRAIL resistance in cancer treatment.
    Selvarajoo K
    Prog Biophys Mol Biol; 2017 Sep; 128():142-154. PubMed ID: 28286052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systems Biology Strategy Reveals PKCĪ“ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma.
    Hayashi K; Tabata S; Piras V; Tomita M; Selvarajoo K
    Front Immunol; 2014; 5():659. PubMed ID: 25601862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells.
    Zhao J; Lu Y; Shen HM
    Cancer Lett; 2012 Jan; 314(1):8-23. PubMed ID: 22030255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is TRAIL the holy grail of cancer therapy?
    Newsom-Davis T; Prieske S; Walczak H
    Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
    Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
    Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining rules for cancer cell proliferation in TRAIL stimulation.
    Deveaux W; Hayashi K; Selvarajoo K
    NPJ Syst Biol Appl; 2019; 5():5. PubMed ID: 30792889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia regulates TRAIL sensitivity of colorectal cancer cells through mitochondrial autophagy.
    Knoll G; Bittner S; Kurz M; Jantsch J; Ehrenschwender M
    Oncotarget; 2016 Jul; 7(27):41488-41504. PubMed ID: 27166192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.
    Huang Y; Yang X; Xu T; Kong Q; Zhang Y; Shen Y; Wei Y; Wang G; Chang KJ
    Int J Oncol; 2016 Jul; 49(1):153-63. PubMed ID: 27210546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL and targeting cancer cells: between promises and obstacles.
    Limami Y; Pinon A; Riaz A; Simon A
    Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):33-8. PubMed ID: 26518894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial dynamics of TRAIL death receptors in cancer cells.
    Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
    Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).
    Mellier G; Pervaiz S
    Free Radic Res; 2012 Aug; 46(8):996-1003. PubMed ID: 22559302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
    Cordier SM; Papenfuss K; Walczak H
    Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
    Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
    J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bio-active Natural Products with TRAIL-Resistance Overcoming Activity.
    Ahmed F; Ishibashi M
    Chem Pharm Bull (Tokyo); 2016; 64(2):119-27. PubMed ID: 26833440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas.
    Alexiou GA; Tsamis KI; Kyritsis AP
    Semin Pediatr Neurol; 2015 Mar; 22(1):35-9. PubMed ID: 25976259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance?
    Plantivaux A; Szegezdi E; Samali A; Egan L
    Ann N Y Acad Sci; 2009 Aug; 1171():38-49. PubMed ID: 19723036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.